NCT00432237View on ClinicalTrials.gov

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,703

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Migraine
Interventions
DRUG

MK0974 50 mg

DRUG

MK0974 150 mg

DRUG

MK0974 300 mg

DRUG

Comparator: Placebo

MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00432237 - Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016) | Biotech Hunter | Biotech Hunter